Search results
Using key discoveries in the field of liver health, we’re advancing treatments for rare and serious liver diseases. Our portfolio is based on novel scientific targets with the potential for therapeutic application across multiple liver diseases.
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH ...
1 day ago · Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. Its product candidates include Ocaliva (obeticholic (OCA)) for liver fibrosis due to nonalcoholic ...
Leadership. Our executive leadership taps into an expertise in liver health and strong business acumen. SEE WHO’S WHO. Vivek Devaraj, President – U.S. and Chairman.
Jun 22, 2023 · Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis...
Dec 20, 2021 · Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary...
Jan 19, 2023 · Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary...
Feb 29, 2024 · Intercept is a biopharmaceutical company and a wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver...
Nov 8, 2023 · Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis...
At Intercept, we keep people at the center of all we do. We’re dedicated to building a healthier tomorrow for people with rare and serious liver diseases.
